Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Past and present cosmetic iris implants: perils and progress

Poster Details

First Author: A.Mansour LEBANON

Co Author(s):                        

Abstract Details

Purpose:

Numerous cases of ocular morbidity following New Colorâ„¢ cosmetic iris implants in Panama have included the following complications: corneal decompensation, uveitis, hyphema, glaucoma, and cataract. Since then other companies have sprung up in India, Jordan, Lebanon, Mexico, Turkey, and Tunisia that claim to be implanting a newer and safe type of implant (Bright Ocular). Little is known about this implant as there is no published medical literature. We present 4 subjects who had ocular morbidity with 3 types of implants: old models that include New Color, Human Optics; and the newest Bright Ocular.

Setting:

Tertiary clinics in 4 countries.

Methods:

We present 4 healthy young Caucasian subjects that underwent cosmetic iris implants (in Tunisia, Lebanon, Syria, and Panama) and developed glaucoma uveitis (2 old implants) or chronic mild to moderate anterior nongranulomatous uveitis (Bright Ocular).

Results:

The patients with the old models developed glaucoma and uveitis requiring several surgeries including explantation. Visual acuity, intraocular pressure, corneal and lens clarity were normal with the Bright Ocular implant in 2 cases. Topical corticosteroid controlled the uveitis partially but surgical removal was necessary. Anterior OCT revealed the implant abutting the peripheral iris.

Conclusions:

Old models of cosmetic iris implants have high ocular morbidity glaucoma and uveitis. BrightOcular is characterized by chronic low grade uveitis. Clinicians should be aware of this new implant, should monitor these patients for iritis and are best treated by explantation.

Financial Disclosure:

NONE

Back to Poster listing